Samsung Bioepis Reveals Ustekinumab Progress

Company Delivers Phase I Data For SB17 Proposed Biosimilar To Stelara

 
• By Dave Wallace

Samsung Bioepis has reported positive Phase I data for its SB17 ustekinumab candidate, a proposed biosimilar to Stelara.

Clinical Trial Icon
Samsung Bioepis reports Phase I data for its ustekinumab • Source: Shutterstock

More from Biosimilars

More from Products